LPAA

11.1700.00%
BG

Brian G. Atwood

Independent Director

Mr. Brian G. Atwood, MBA, MS, Veracyte is Independent Director of Launch One Acquisition Corp. from July 2024. Mr. Atwood serves as Director of CERo Therapeutics Inc. He was Chairman, President and Chief Executive Officer at CERo Therapeutics Holdings, Inc since February 14, 2024 until September 30, 2024 and also serves as Director since February 14, 2024. He was Co-Founded at Versant Venture Management, LLC till 2022 and was its Managing Director. He previously served as Chairman of PBAX from October 2021 the Closing of the Business Combination in February 2024. Mr. Atwood co-founded Versant Ventures, Inc. in 1999 and serves as its Managing Director. He specialized in biotechnology investing at Versant. Mr. Atwood served as an Independent Chairman of the Board at Locust Walk Acquisition Corp. since January 2021 until August 2021. He had been the Chairman of the board at Atreca, Inc. since December 2013 until April 2024 and its Independent Director since 2013. Prior to founding Versant Ventures, Mr. Atwood served as a general partner of Brentwood Associates, a venture capital firm. From December 2015 until February 2018, he served as President and Chief Executive Officer and was a co-founder of Cell Design Labs, Inc. He co-founded Perkin Elmer and Cetus Instruments. Under his management, the venture developed and launched the GeneAmp® Polymerase Chain Reaction (PCR) system. He served as a General Partner at Brentwood Venture Capital from November 1995 to October 1998, where he led investments in biotechnology, pharmaceuticals and bioinformatics. He served as an Independent Chairman at Phoenix Biotech Acquisition Corp. since October 2021 until February 2024. He founded Glycomed Incorporated and served as its President and Chief Executive Officer from December 1993 to May 1995 and as a Vice President of Operations from July 1988 to November 1993. At Glycomed, he concentrated on business development and strategic alliances, closing deals with Eli Lilly & Company, Millipore, Genentech and Sankyo, before leading the sale of Glycomed to Ligand Pharmaceuticals. From March to December 1995, he served as a Consultant on business development at Coulter Pharmaceutical, Inc. He serves as Director of Cell Design Labs, Inc. He serves on the boards of several pharmaceutical and biotechnology companies. He has been a Director at Clovis Oncology, Inc. since April 2009 until July 2023. Mr. Atwood had been an Independent Director of Cadence Pharmaceuticals Inc. since March 2006 until March 2014. He serves as a Director of Clovis Pharmaceuticals; Spark Diagnostics, Inc. Calderome, Inc.; VaccSys Inc. and Synosis Therapeutics. He has been a Director of PhaseRx, Inc. since February 2008. He serves as a Director of Biotechnology Innovation Organization, Groove BioPharma Corporation. He had been a Director of Trius Therapeutics, Inc. since February 2007 until September 2013. He has been a Director and a Member of Emerging Companies Section Governing Board at Biotechnology Industry Organization since July 2011. He serves as a Member of Advisory Board at QB3. Mr. Atwood served as Director of OpGen, Inc. since July 2007 until June 8, 2017. He served as the Chairman of the Board at Veracyte, Inc. from February 2008 to December 12, 2016. He served as a Director of Reviva Pharmaceuticals, Inc. since March 10, 2015. He served as the Chairman at Five Prime Therapeutics, Inc. from January 2012 to March 11, 2016. He served as the Chairman of Intarcia Therapeutics, Inc. from August 1997 to December 2004. He was Director of Pharmion Corporation from 2000 until its acquisition in March 2008. He served as a Director at Immune Design Corp. from May 2008 to June 15, 2016. He served as a Director of Five Prime Therapeutics, Inc. from May 2012 to March 11, 2016. He served as a Director of Salmedix Inc. since January 2001. He served as a Director of Veracyte, Inc. from December 2006 to December 12, 2016. He served as a Director of Pharmion LLC from January 2000 to March 2008, Helicos BioSciences Corporation since 2003 until September 2011, Biotie Therapies AG until January 2009, DNA Sciences, Inc. since March 1999, Coulter Pharmaceutical, Inc. since April 1996, Xenogen Corporation since January 1998 and Intarcia Therapeutics, Inc. until December 2004. He served as a Director at FeRX Incorporated, ForteBio, Inc. VLST Corporation, Entelos, Inc.; BioSpace.com, Inc. Theraclone Sciences, Inc. Saegis Pharmaceuticals, Inc. and Jazz Pharmaceuticals Public Limited Company. He served as a Board Observer and Director of Accelerator Corporation. He served as a Director at Perkin Elmer and Cetus Instruments. His years evaluating biotech deals as a VC and working as an entrepreneurial Chief Executive Officer have given him insight into both roles in the venture capital ecosystem. He has operating experience in the biotechnology industry, with emphasis on therapeutic products, devices, diagnostics and research instrumentation. Mr. Atwood holds a B.S. in Biological Sciences from the University of California, Irvine, a M.S. in Ecology from the University of California, Davis and a M.B.A. from Harvard Business School.

公司职务